TY - JOUR
T1 - Endoscopic sleeve gastroplasty (ESG) is a reproducible and effective endoscopic bariatric therapy suitable for widespread clinical adoption
T2 - A large, international multicenter study
AU - Sartoretto, Adrian
AU - Sui, Zhixian
AU - Hill, Christine
AU - Dunlap, Margo
AU - Rivera, Angielyn R.
AU - Khashab, Mouen A.
AU - Kalloo, Anthony N.
AU - Fayad, Lea
AU - Cheskin, Lawrence J.
AU - Marinos, George
AU - Wilson, Erik
AU - Kumbhari, Vivek
N1 - Publisher Copyright:
© Springer Science+Business Media, LLC, part of Springer Nature 2018.
PY - 2018/2/15
Y1 - 2018/2/15
N2 - Objective Endoscopic sleeve gastroplasty (ESG), an incisionless endoscopic bariatric procedure, has shown impressive results in case series. This study examines the reproducibility, efficacy, and safety in three centers across two countries, and identifies key determinants for procedural success. Design Patients who underwent ESG between February 2016 and May 2017 at one of three centers (Australia and USA) were retrospectively analyzed. All procedures were performed on an outpatient basis using the Apollo OverStitch device (Apollo Endosurgery, Austin, TX). Primary outcomes included absolute weight loss (ΔWeight, kg), change in body mass index (ΔBMI, in kg/m 2 ), total body weight loss (TBWL, %), excess weight loss (EWL, in %), and immediate and delayed adverse events. Results In total, 112 consecutive patients (male 31%, age 45.1 ± 11.7 years, baseline BMI 37.9 ± 6.7 kg/m 2 ) underwent ESG. At 1, 3, and 6 months, Δweight was 9.0 ± 4.6 kg (TBWL 8.4 ± 4.1%), 12.9 ± 6.4 kg (TBWL 11.9 ± 4.5%), and 16.4 ± 10.7 kg (TBWL 14.9 ± 6.1%), respectively. The proportion of patients who attained greater than 10% TBWL and 25% EWL was 62.2 and 78.0% at 3 months post-ESG and 81.0 and 86.5% at 6 months post-ESG. Weight loss was similar between the three centers. Multivariable analysis showed that male sex, greater baseline body weight, and lack of prior endoscopic bariatric therapy were predictors of greater Δweight at 6 months. Three (2.7%) severe adverse events were observed. Conclusions ESG is an effective, reproducible, and safe weight loss therapy that is suitable for widespread clinical adoption.
AB - Objective Endoscopic sleeve gastroplasty (ESG), an incisionless endoscopic bariatric procedure, has shown impressive results in case series. This study examines the reproducibility, efficacy, and safety in three centers across two countries, and identifies key determinants for procedural success. Design Patients who underwent ESG between February 2016 and May 2017 at one of three centers (Australia and USA) were retrospectively analyzed. All procedures were performed on an outpatient basis using the Apollo OverStitch device (Apollo Endosurgery, Austin, TX). Primary outcomes included absolute weight loss (ΔWeight, kg), change in body mass index (ΔBMI, in kg/m 2 ), total body weight loss (TBWL, %), excess weight loss (EWL, in %), and immediate and delayed adverse events. Results In total, 112 consecutive patients (male 31%, age 45.1 ± 11.7 years, baseline BMI 37.9 ± 6.7 kg/m 2 ) underwent ESG. At 1, 3, and 6 months, Δweight was 9.0 ± 4.6 kg (TBWL 8.4 ± 4.1%), 12.9 ± 6.4 kg (TBWL 11.9 ± 4.5%), and 16.4 ± 10.7 kg (TBWL 14.9 ± 6.1%), respectively. The proportion of patients who attained greater than 10% TBWL and 25% EWL was 62.2 and 78.0% at 3 months post-ESG and 81.0 and 86.5% at 6 months post-ESG. Weight loss was similar between the three centers. Multivariable analysis showed that male sex, greater baseline body weight, and lack of prior endoscopic bariatric therapy were predictors of greater Δweight at 6 months. Three (2.7%) severe adverse events were observed. Conclusions ESG is an effective, reproducible, and safe weight loss therapy that is suitable for widespread clinical adoption.
KW - Endoscopic bariatric therapy
KW - Endoscopic sleeve gastroplasty
KW - Endoscopic suturing
KW - Obesity
KW - Weight loss
UR - http://www.scopus.com/inward/record.url?scp=85042133740&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042133740&partnerID=8YFLogxK
U2 - 10.1007/s11695-018-3135-x
DO - 10.1007/s11695-018-3135-x
M3 - Article
C2 - 29450845
AN - SCOPUS:85042133740
SN - 0960-8923
VL - 28
SP - 1812
EP - 1821
JO - Obesity Surgery
JF - Obesity Surgery
IS - 7
ER -